Lucerastat (Standard)
Lucerastat (Standard) is the analytical standard of Lucerastat. This product is intended for research and analytical applications. Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS) . Lucerastat has the potential for Fabry disease study[1][2].
Product Specifications
CAS Number
141206-42-0
Product Name Alternative
NB-DGJ (Standard) ; N- (n-Butyl) deoxygalactonojirimycin (Standard)
UNSPSC
12352005
Target
Glucosylceramide Synthase (GCS) ; Reference Standards
Related Pathways
Neuronal Signaling; Others
Field of Research
Metabolic Disease
Smiles
O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O
Molecular Formula
C10H21NO4
Molecular Weight
219.28
References & Citations
[1]Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.|[2]R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSH031355 100 µg
Recombinant Human H1F0/Histone H1 Protein (His Tag)
Sign In for Pricing
View Details 
BNUB1887-500 1x 500 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (MUC1/1887R), 0.2mg/mL
Sign In for Pricing
View Details 
